Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) signed the share acquisition agreement to acquire 51% stake in Shanxi Simaile Pharmaceutical Chain Co., Ltd. from Yang Jinjiang, Liu Hongming for approximately CNY 330 million on September 18, 2023. Shanxi Simaile Pharmaceutical Chain Co., Ltd. reported Total assets worth CNY 280.7 million and Total Common equity of CNY 74.7 million in April 2023. Transaction was already approved by Hunan Dajiaweikang Pharmaceutical Industry's board of director's.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.39 CNY | +3.19% | -2.29% | -27.94% |
1st Jan change | Capi. | |
---|---|---|
-27.94% | 259M | |
+26.31% | 76.86B | |
-1.79% | 24.12B | |
+6.85% | 8.71B | |
+11.36% | 8.57B | |
-23.95% | 7.67B | |
+15.02% | 5.25B | |
+1.51% | 4.12B | |
-8.25% | 3.88B | |
+17.02% | 3.55B |
- Stock Market
- Equities
- 301126 Stock
- News Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd
- Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed the share acquisition agreement to acquire 51% stake in Shanxi Simaile Pharmaceutical Chain Co., Ltd. from Yang Jinjiang, Liu Hongming for approximately CNY 330 million.